secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2023-02-09T23:59:59+00:00
Accession:  0000950170-23-002384
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma launches $50M public offering of 22.2M shares at $2.25; plans Phase 2 SSc-ILD study
--------------------------------------------------------------------------------

- Gross proceeds ~$50M from 22,225,000 shares at $2.25; underwriters have 30-day option for 3,333,750 additional shares.
- FDA cleared IND for efzofitimod in SSc-ILD; Phase 2 proof-of-concept study planned for 2023.
- Phase 2 study: 28-week, randomized, double-blind, placebo-controlled, 2:2:1 dosing 270 mg, 450 mg efzofitimod or placebo; 25 patients.
- Orphan drug designations: FDA: sarcoidosis (Jan 2022) and systemic sclerosis (Apr 2022); EU: sarcoidosis (Jan 2023).
- Risk factor supplement: no guarantee of orphan drug exclusivity for future indications or jurisdictions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017023002384/0000950170-23-002384-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017023002384/life-20230208.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-002384

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer